Following the close of the deal, Opko's diagnostic services will be merged with Bio-Reference's operations.
The contracts with Stratose, Three Rivers Provider Network, and Fortified Provider Network provide coverage for Opko's testing services.
The deal is still subject to other closing conditions including the approval of BRL's shareholders.
The firm said that revenues per patient were up 3 percent, while the number of patients served grew 8 percent.
Opko plans to leverage BRL's national marketing, sales, and distribution resources to enhance the sale of its blood-based 4Kscore test for aggressive prostate cancer.
NEW YORK (GenomeWeb) – Opko Health said this week that it has launched sales of its 4Kscore prostate cancer risk test in additional European territories.
Opko Health this week announced the launch of its 4Kscore prostate cancer test, which it will offer out of its Nashville, Tenn.-based CLIA lab.
Somalogic said this week that it has named Dan Muehl as chief financial officer.
Opko Health has appointed Greg Stanley vice president of sales and marketing for its global diagnostics business unit.
Opko Health said this week that it has purchased Uruguayan pharmaceutical company Laboratorio Arama de Uruguay Limited.
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.